Highest-materiality recent filing
DocGo shareholders approve reverse stock split, reject two charter amendments
Elected directors Vina Leite (31.2M votes for) and James M. Travers (25.1M votes for) to Class II.
DocGo Q1 revenue $75.6M (down 21% YoY) as migrant programs end; raises FY rev guidance to $300-315M
Total revenue $75.6M vs $96.0M YoY; migrant-related revenue zero vs $35M. Ex-migrant revenue up 19.3% to $75.6M.
Dr. Stephen Klasko will step down from the Board effective after the 2026 Annual Meeting on June 16, 2026, due to a new healthcare leadership role.
Q4 2025 revenue $74.9M (down 38% YoY due to migrant wind-down); net loss $142.3M vs $7.6M loss in Q4 2024.
DocGo receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified DocGo on Jan 26, 2026 of non-compliance with minimum bid price rule; closing bid below $1.00 from Dec 9, 2025 to Jan 23, 2026.
DocGo extends $26M share repurchase program expiration to June 30, 2026
Board extended buyback deadline from Dec 31, 2025 to June 30, 2026; no other changes.
DocGo Q3 revenue $70.8M, net loss $29.7M; migrant wind-down drives decline
Revenue $70.8M (-49% YoY); ex-migrant rev $62.4M (+8%). Migrant rev fell to $8.4M from $80.7M.
DocGo acquires SteadyMD for up to $25M; common/preferred holders receive no closing cash
Acquisition via merger: $12.5M cash at closing plus up to $12.5M contingent earn-out.
DocGo acquires SteadyMD for up to $25M, expands telehealth across 50 states
Acquisition price up to $25M: $12.5M cash at close + up to $12.5M contingent earn-out.
DocGo Q2 revenue halved to $80.4M from migrant wind-down; net loss $13.3M
Revenue $80.4M vs $164.9M YoY due to planned migrant program wind-down; net loss $13.3M vs net income $5.9M.
DocGo shareholders reject two charter amendments at 2025 annual meeting
Elected three Class I directors: Bienstock (57.2M for), Tendler (50.7M for), Smedra (43.9M for).
DocGo extends $26M share repurchase program expiration to Dec 31, 2025
Board extended repurchase program expiration from June 30, 2025 to December 31, 2025.
Q1 2025 revenue $96.0M vs $192.1M YoY; net loss $11.1M vs net income $10.6M.
DocGo Q4 revenue $120.8M, net loss $7.6M; FY 2025 EBITDA margin guidance cut to ~5%
Q4 2024 revenue $120.8M, down from $199.2M Q4 2023 on migrant wind-down; net loss $7.6M vs net income $8.0M.
DocGo extends share repurchase program expiration to June 30, 2025
Board extended expiration of $26M share repurchase program from Dec 31, 2024 to June 30, 2025.
DocGo Q3 2024 revenue falls 26% to $138.7M; raises FY2024 cash flow guidance to $90-100M
Q3 revenue $138.7M (-26% YoY) from migrant program wind down; net income $4.5M (flat YoY).
DocGo appoints Dr. Stephen K. Klasko as independent Chair; Steven Katz resigns
Dr. Klasko appointed Class III director and independent Chair of Board effective October 1, 2024.
DocGo Q2 revenue $164.9M (+31% YoY), net income $5.9M; raises cash flow guidance to $80-90M
Revenue $164.9M (up 31% YoY); net income $5.9M (up 354%); adjusted EBITDA $17.2M (up 89%).
DocGo Inc. announces 2024 Annual Meeting results; all proposals approved by stockholders
Both Class III director nominees Steven Katz and Michael Burdiek elected with 38.8M and 50.7M votes for respectively.
DocGo Q1 revenue up 70% to $192.1M; guides FY revenue down to $600-650M on migrant wind-down
Net income of $10.6M vs loss of $3.9M YoY; record adjusted EBITDA $24.1M, up 330%.
DocGo discloses cybersecurity incident involving protected health information in ambulance business
Unauthorized access to certain systems; threat actor acquired data including protected health information.
DocGo subsidiary extends NYC asylum-seeker services contract through Dec 2024
RRT entered a letter agreement with NYC HPD extending the contract to December 31, 2024.
DocGo founder Stan Vashovsky retires as director/chair; CEO Bienstock joins board; Katz new chair
Stan Vashovsky steps down as director and Chair of Board effective March 31, 2024; remains as consultant until March 31, 2025.
DocGo Q4 revenue $199.2M (+83% YoY); guides 2024 $720-750M rev, $80-85M adj EBITDA
Q4 revenue $199.2M (+83% YoY); net income $8.0M (+13%); adjusted EBITDA $22.6M (+232%).
DocGo announces $36M share buyback program, cites strong cash position and undervaluation
Board approved up to $36M in share repurchases over 6 months ending July 30, 2024.
DocGo refutes short seller claims; projects 40% revenue growth in FY2023
Select preliminary FY2023 results indicate ~40% revenue growth, following 84% CAGR from 2016-2022.
DocGo rejects Fuzzy Panda short report; guides FY2024 revenue >$700M
FY2023 revenue expected $615-625M, in line with prior guidance.
DocGo Q3 revenue $186.6M (+79% YoY); raises FY23 revenue guidance to $615-$625M
Revenue $186.6M (+79% YoY, +49% QoQ); net income $4.6M (+84% YoY).
DocGo receives positive OTDA review; HPD payments commence October 24
NYC Comptroller registered HPD agreement Sept 15; DocGo began receiving payments Oct 24, 2023.
DocGo finalizes separation agreement with former CEO Anthony Capone; $45k monthly consulting
Anthony Capone resigned as CEO Sept 15; consulting role through March 15, 2024.
DocGo CEO Anthony Capone resigns; President Lee Bienstock appointed CEO
Anthony Capone resigned as CEO and all other positions effective September 15, 2023, for personal reasons.
HPD assures DocGo it will compel NYC Comptroller to process payments under asylum-seeker contract
NYC Comptroller returned DocGo's HPD contract without approval on Sept 5.
DocGo EVP/Treasurer Oberholzer moves to EVP of Strategy; CFO Rosenberg assumes Treasurer role
Andre Oberholzer steps down as Treasurer and EVP of Capital Markets and Strategy, effective immediately; becomes EVP of Strategy reporting to CEO.
DocGo Q2 revenue $125.5M, raises FY2023 revenue guidance to $540-550M
Total revenue $125.5M, up 15% sequentially; net income $1.3M vs net loss $3.9M in Q1.
DocGo shareholders elect two Class II directors, ratify auditor at 2023 annual meeting
Vina Leite elected with 57.4M votes for, 3.1M withheld, 16.0M broker non-votes.
DocGo holds Investor Day; no material financial updates disclosed
Investor Day held on June 20, 2023, with presentations on strategy, operations, and clinical excellence.
DocGo Q1 revenue $113M, net loss $3.9M; reaffirms FY2023 guidance
Q1 revenue $113.0M, down 4.2% YoY; ex-COVID testing, revenue up 40.2%.
DocGo appoints Vina Leite to Compensation and Nominating committees
Vina Leite was elected as a Class II director effective November 10, 2022, when the Board was expanded to seven members.
DocGo raises CEO salary to $600k, approves stock awards worth ~$410k
Base salary increased from $425,000 to $600,000; target bonus raised from 73% to 100% of base, effective Apr 1, 2023.
DocGo appoints President, Treasurer, CFO; approves salary increases and stock option grants
Lee Bienstock appointed President (in addition to COO); salary raised to $490K from $415K, target bonus increased to 80% from 50%.
DocGo FY2022 revenue $440.5M (+38% YoY); guides 2023 revenue $500-$510M, Adj. EBITDA $45-50M
Full-year 2022 revenue $440.5M, up 38% YoY; net income $30.7M (+60%); Adjusted EBITDA $41.3M (+65%).
DocGo CEO Vashovsky retires but stays as non-executive Chairman; Capone becomes CEO
Stan Vashovsky steps down as CEO effective Dec 31, 2022, but remains non-executive Chairman from Jan 1, 2023.
DocGo appoints Leite to board, promotes Bienstock to President, names Rosenberg CFO
Appointed Vina Leite, Chief People Officer at GoodRx, to its Board of Directors.
DocGo Q3 revenue $104.3M (+22% YoY), net income up 213%; raises FY guidance, CEO retiring
Q3 revenue $104.3M (up 22% YoY); net income $2.5M vs $0.8M (up 213%); adj. EBITDA $8.4M vs $4.0M (up 110%).
DocGo enters $90M revolving credit facility with Citibank; includes $50M accordion option
$90M secured line of credit with Citibank as administrative agent, five-year maturity.
DocGo redeems all outstanding warrants at $0.10 each; deadline Sept 16, 2022
Redemption price of $0.10 per warrant; warrants must be exercised by 5:00pm ET on Sept 16 or become void.
DocGo Q2 revenue $109.5M (+76% YoY), raises FY2022 guidance to $425-435M
Revenue $109.5M, up 76% YoY from $62.2M; net income $11.8M vs $0.1M.
DocGo Inc. elects three Class I directors, ratifies auditor at 2022 annual meeting
Stan Vashovsky elected with 64.3M for, 4.2M withheld; Ira Smedra 63.1M for, 5.4M withheld.
DocGo announces $40M share repurchase program, citing strong cash position and confidence
Board authorizes repurchase of up to $40M of common stock; program expires Nov 24, 2023.
DocGo Q1 revenue $117.9M (up 137% YoY), net income $9.4M vs loss; reaffirms FY22 guidance $400-420M
Q1 revenue $117.9M (up 137% YoY); net income $9.4M vs net loss $2.0M in Q1 2021.
On September 25, 2024, Mr. Katz notified the Board that he intends to step down as a director and Chair of the Board, effective as of the Effective Date.
On September 26, 2024, the Board of Directors (the “Board”) of DocGo Inc. (the “Company”) appointed Stephen K. Klasko, MD as a Class III director and independent Chair of the Board, effective as of October 1, 2024 (the “Effective Date”).
on March 7, 2024, Mr. Vashovsky notified the Board that he intends to retire and step down as a director and Chair of the Board, effective as of March 31, 2024.
On March 7, 2024, the Board of Directors (the “Board”) of DocGo Inc. (the “Company”) appointed Lee Bienstock, Chief Executive Officer of the Company, to the Board as a Class I director, effective as of April 1, 2024 following Stan Vashovsky’s departure as a director and Chair of the Board on March 31, 2024.
on March 7, 2024, the Board appointed director Steven Katz to succeed Mr. Vashovsky as Chair of the Board, effective as of April 1, 2024.
on March 7, 2024, Mr. Vashovsky notified the Board that he intends to retire and step down as a director and Chair of the Board, effective as of March 31, 2024.
As previously reported, Anthony Capone resigned as the Chief Executive Officer of DocGo Inc. (the “Company”) effective September 15, 2023.
Anthony Capone resigned as the Chief Executive Officer of DocGo Inc. (the “Company”) and from all other positions with the Company due to personal reasons.
On September 15, 2023, the Board of Directors of the Company (the “Board”) appointed Lee Bienstock, the Company’s current President and Chief Operating Officer, as the Chief Executive Officer of the Company, effective immediately.
As previously disclosed, current President Anthony Capone will assume the role of the Company’s Chief Executive Officer beginning on January 1, 2023, and Mr. Smedra will continue serving as a director on the Board.
On December 29, 2022 the Company announced that, while Mr. Vashovsky will retire as the Chief Executive Officer of the Company, as previously disclosed, he will continue serving as a non-executive Chairman of the Board given the strong growth outlook for the Company.
Mr. Norman Rosenberg will succeed Mr. Oberholzer as the Chief Financial Officer of the Company
Max materiality 0.85 · Median 0.65 · Most common event earnings